Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00542841 · ClinicalTrials.gov registry record · NA
Examining Genetic Differences Among People With 21-Hydroxylase Deficiency
A NA study of 21-Hydroxylase Deficiency, sponsored by Maria I. New.
- Completed
- Registry status
- NA
- Development phase
- 99
- Enrollment target
- 3
- Study locations
NCT00542841 is a NA study of 21-Hydroxylase Deficiency that has completed, run by Maria I. New. The registered enrollment target is 99 participants. The trial reports 3 study locations across 3 states.
The verdict
NCT00542841, a NA study of 21-Hydroxylase Deficiency, has completed, sponsored by Maria I. New.
- COMPLETED
- Registry status
- NA
- Development phase
- 99 participants
- Enrollment target
- 3
- Study locations
Study Summary
Congenital adrenal hyperplasia (CAH) is a genetic disorder that affects the amount of steroids that the body forms. The most common form of CAH is 21-hydroxylase deficiency (21OHD), which leads to cortisol deficiency. This, in turn, causes the development of mature masculine characteristics in newborn, prepubescent, and grown females and in prepubescent males. 21OHD is known to be caused by the mutation of a specific gene. However, symptom severity among people with 21OHD varies, and adults seem to be less affected than children. This study will examine participants' DNA to determine what other genes may affect the severity of 21OHD and may make the disease milder in adults than in children.
Conditions Studied
Interventions
- PROCEDURE Hydrocortisone withdrawal
Study Locations (3)
New York
- Mount Sinai School of Medicine - New York
Texas
- University of Texas Southwestern Medical Center - Dallas
São Paulo
- University of Sao Paolo - São Paulo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2007-08 |
| Est. Completion | 2009-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00542841
The ClinicalTrials.gov registry entry for NCT00542841 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Maria I. New, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with 21-Hydroxylase Deficiency appearing as the primary indexed condition, and to 1 intervention - of which Hydrocortisone withdrawal is the first listed.
NCT00542841 reports 3 study locations spanning 3 distinct geographic areas - top geographies include New York, Texas, São Paulo.
Frequently Asked Questions
What is clinical trial NCT00542841 about?
NCT00542841 is a clinical study titled "Examining Genetic Differences Among People With 21-Hydroxylase Deficiency". Congenital adrenal hyperplasia (CAH) is a genetic disorder that affects the amount of steroids that the body forms. The most common form of CAH is 21-hydroxylase deficiency (21OHD), which leads to cortisol deficiency. This, in turn, causes the development of mature masculine characteristics in newbo...
What is the current status of trial NCT00542841?
This trial is currently completed. It is a NA study. The enrollment target is 99 participants. The study started on 2007-08. Estimated completion is 2009-03.
What conditions does trial NCT00542841 study?
This clinical trial studies the following conditions: 21-Hydroxylase Deficiency.
What interventions are being tested in trial NCT00542841?
The interventions under investigation include: Hydrocortisone withdrawal (PROCEDURE).
Who is sponsoring clinical trial NCT00542841?
This trial is sponsored by Maria I. New, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00542841 being conducted?
This trial has 3 study locations across New York, Texas, São Paulo. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for 21-Hydroxylase Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.